Study record

Adropin and MOTS-c as new peptides: Do levels change in neurodegenerative diseases and ischemic stroke?

Saçmacı H, Çakır M, Özcan SS · J Biochem Mol Toxicol · 2023

Human obs.Endogenous MOTS-c measuredEvidence tier B
PubMed 36303331doi:10.1002/jbt.23246Compare with another study

What this study reported

Measured plasma adropin and MOTS-c alongside neuron-specific enolase and neurofilament light chain in adults with neurodegenerative disease, acute ischemic stroke or multiple sclerosis and in controls. Reported lower plasma MOTS-c in the acute ischemic stroke and Alzheimer's disease groups than in controls, with no significant difference in the multiple sclerosis group. Reported that MOTS-c levels correlated positively with platelet, lymphocyte and triglyceride levels in this cohort.

Limitations

Small cross-sectional subgroups of 32 patients each with no longitudinal follow-up, so temporal direction cannot be established; the reported results statement is ambiguously worded about which group showed which change.

Study record

Annotated fields for this study
Study modelHuman observational
Substance studiedEndogenous MOTS-c measuredNaturally occurring MOTS-c was measured; nothing was given.
Specieshuman
System studiedPatients with Alzheimer's disease, Parkinson's disease, acute ischemic stroke or multiple sclerosis and matched controls
Populationadults with Alzheimer's disease, Parkinson's disease, acute ischemic stroke or multiple sclerosis, each with group-appropriate controls
DesignCase-control study with ELISA measurement of plasma peptides
Sample size as reported32 patients in each disease subgroup plus group-appropriate controls
Control groupgroup-appropriate control participants
Route (data field only)Not reported
Endpoints measuredplasma MOTS-c; plasma adropin; neuron-specific enolase; neurofilament light chain; haematological and biochemical parameters
Pathways measuredNot reported
Research areasNervous system · Cardiovascular
Evidence tierB — Other human study
Publication typesJournal Article

Appraisal

Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.

Relevance to MOTS-c
Direct
Model applicability
Human
Sample size
Small
Controls
Appropriate
Outcome validity
Exploratory
Support for its own conclusion
Weak

Provenance

  • Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
  • Annotated from the published abstract.
  • Editorial review: approved (2026-11-11).
  • Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.